亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Pharmacological Screen to Identify Compounds That Facilitate NO signaling in Muscle With Deficient nNOS Localization and/or Activity

詳細技術說明
Technology DescriptionResearchers have discovered a newoption for treating muscular dystrophy and other diseases associated withmuscle wasting symptoms. This option consists of the administration ofsildenafil (or another inhibitor of phosphodiesterase 5A) in affected patients priorto exercise or similar activity. The effects of this treatment areattributed to the known mechanism of action for these agents, which is theprevention of cGMP degradation. cGMP is a key messenger for initiatingvasodilation and thus increasing blood flow. When this treatment is instituted,the cGMP persists longer in smooth muscle cells and the resulting vasodilationalso persists for a greater period of time. This increase in blood flow toactive muscles slows their rate of fatigue and limits the activity-inducedmuscle tissue damage associated with myopathic conditions.Advantages Novel mechanism of action. Phosphodiesterase inhibitors work via the preservation of cGMP in blood vessels, which initiates vasodilation. It is believed that the absence of vasodilation and the resulting lack of increased blood flow play a key role in rapid muscle fatigue and muscle cell breakdown.Well-established safety profile. Sildenafil and other phosphodiesterase inhibitors have been used clinically for many years and have shown themselves to be safe for long-term use.
*Abstract
Background

There are a variety of diseases thatcause muscle weakness and muscle tissue breakdown (myopathy). The most notableof these diseases are the muscular dystrophies, but can also include suchdiverse conditions as HIV infection cancer, and aging. The symptoms ofmyopathy have a variety of causes, but all result in various levels ofdebilitation to the patient. A treatment that could slow or prevent theprogression of muscle weakness from various causes would have significant valueto patients.

*Licensing
Email: uirf-marketing@uiowa.eduPhone: (319) 335-4546
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備